Hyperprolactinaemia. Hyperprolactinaemia
Conditions
Interventions
Intervention 1: Medication administration ( marticaria chamomilla syrup) 5 cc two times a day for 4 weeks. Intervention 2: Cabergoline 0.25 mg twice a week.
Treatment - Drugs
Medication administration ( marticaria chamomilla syrup) 5 cc two times a day for 4 weeks.
Sponsors
Dr. Minaei; Vice chancellor for research Traditional Medicine Faculty of Tehran University of Medica
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patient satisfaction; Female; Outpatients older than 18 years; Patient with asymptomatic or mild symptoms idiopathic hyperprolactinemia (menstrual disorders that are just starting with or without galactorrhea or without bothering galactorrhea alone); Serum prolactin level above 25 µgr/L Exclusion criteria: Patients older than 45 years; Patient with liver failure; Patient with kidney failure; Patient with hypothyroidism; Taking medication such as haloperidol, phenothiazine, butyrophenone, monoamine oxidase inhibitor, fluoxetine, sulpiride, metoclopramide, domperidone, tricyclic antidepressants, opioid, estrogen, verapamil, reserpine, methyldopa, benzodiazepine, cimetidine, medroxolol drugs and any medication that is effective in prolactin secretion in the last three months; The use of warfarin; The use of sedating; Prolactinoma( micro or macro adenoma); Adrenal, pituitary and hypothalamus disease; Pregnant women; Women who plan to become pregnant; Breast feeding; Autoimmune disease such as lupus; Long- term menstural disorders; Bothering galactorrhea; Underlying disease such as diabetes, hypertension and cancer; History of hyperprolactinemia treatment in the last 6 months; The use of propranolol and vasoconstrictor drugs; Raynaud’s disease; History sensitivity to ergot derivatives; History of stomach ulcers and gastrointestinal bleeding; Asthma; History of hay fever and allergic reaction to member of the compositae family such as yarrow, feverfew, artemisia, tansy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum prolactin level. Timepoint: Before and after the intervention. Method of measurement: Laboratory measurement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: During the treatment. Method of measurement: questionnaire and Physical exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarya Kabiri
Traditional Medicine Faculty, Tehran University of Medical Sciences
Outcome results
None listed